Evidence map›Paper›PMID 30403572›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2019

Neoadjuvant (Chemo)radiotherapy With Total Mesorectal Excision Only Is Not Sufficient to Prevent Lateral Local Recurrence in Enlarged Nodes: Results of the Multicenter Lateral Node Study of Patients With Low cT3/4 Rectal Cancer.

Atsushi Ogura, Tsuyoshi Konishi, Chris Cunningham, Julio Garcia-Aguilar, Henrik Iversen, Shigeo Toda, In Kyu Lee, Hong Xiang Lee, Keisuke Uehara, Peter Lee and 6 more

2 registry-linked trialsOpen access · greenAbstract readMulticenter Study
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 271 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
271citing papers in PubMed, 14 pooled it
15.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04486131 recruitingnot on this mapstarted 2020, after this paper: background citation

Lateral Nodal Recurrence in Rectal Cancer

TypeobservationalSponsorAmsterdam UMC, location VUmcRan2020 to 2026Enrolled200ConditionsRectal Cancer
NCT05539417 completednot on this map

Snapshot Rectumcarcinoom 2016

TypeobservationalSponsorAmsterdam UMC, location VUmcRan2016 to 2016Enrolled3,107ConditionsRectal Cancer
3 · Its place in the literature

Who cites it

271 citing papers in PubMed, 14 syntheses or guidelines pooled it, 492 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Review
  20. Article

211 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 11 institutions in 7 countries.

Atsushi Ogura1 Leiden University Medical Center, Leiden, the Netherlands.
Tsuyoshi Konishi3 Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Chris Cunningham5 Oxford University Hospitals National Health Service Foundation Trust, Oxford, United Kingdom.
Julio Garcia-Aguilar4 Memorial Sloan Kettering Cancer Center, New York, NY.
Henrik Iversen6 Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.
Shigeo Toda7 Toranomon Hospital, Tokyo, Japan.
In Kyu Lee8 The Catholic University of Korea, Seoul St Mary's Hospital Seoul, Republic of Korea.
Hong Xiang Lee8 The Catholic University of Korea, Seoul St Mary's Hospital Seoul, Republic of Korea.
Keisuke Uehara2 Nagoya University Graduate School of Medicine, Nagoya, Japan.
Peter Lee10 Royal Prince Alfred Hospital and University of Sydney, Sydney, New South Wales, Australia.
Hein Putter1 Leiden University Medical Center, Leiden, the Netherlands.
Cornelis J H van de Velde1 Leiden University Medical Center, Leiden, the Netherlands.
Geerard L Beets11 The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Harm J T Rutten12 Catharina Hospital, Eindhoven, the Netherlands.
Miranda Kusters12 Catharina Hospital, Eindhoven, the Netherlands.
Lateral Node Study Consortium
Leiden University Medical Center · NLCatharina Ziekenhuis · NLSeoul St. Mary's Hospital · KRJapanese Foundation For Cancer Research · JPKarolinska University Hospital · SEMemorial Sloan Kettering Cancer Center · USNagoya University · JPNational Health Service · GBRoyal Prince Alfred Hospital · AUThe Netherlands Cancer Institute · NLToranomon Hospital · JP

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

purposeImprovements in magnetic resonance imaging (MRI), total mesorectal excision (TME) surgery, and the use of (chemo)radiotherapy ([C]RT) have improved local control of rectal cancer; however, we have been unable to eradicate local recurrence (LR). Even in the face of TME and negative resection margins (R0), a significant proportion of patients with enlarged lateral lymph nodes (LLNs) suffer from lateral LR (LLR). Japanese studies suggest that the addition of an LLN dissection (LLND) could reduce LLR. This multicenter pooled analysis aims to ascertain whether LLNs actually pose a problem and whether LLND results in fewer LLRs. PATIENTS AND

methodsData from 1,216 consecutive patients with cT3/T4 rectal cancers up to 8 cm from the anal verge who underwent surgery in a 5-year period were collected. LLND was performed in 142 patients (12%). MRIs were re-evaluated with a standardized protocol to assess LLN features.

resultsOn pretreatment MRI, 703 patients (58%) had visible LLN, and 192 (16%) had a short axis of at least 7 mm. One hundred eight patients developed LR (5-year LR rate, 10.0%), of which 59 (54%) were LLRs (5-year LLR rate, 5.5%). After multivariable analyses, LLNs with a short axis of at least 7 mm resulted in a significantly higher risk of LLR (hazard ratio, 2.060; P = .045) compared with LLNs of less than 7 mm. In patients with LLNs at least 7 mm, (C)RT plus TME plus LLND resulted in a 5-year LLR of 5.7%, which was significantly lower than that in patients who underwent (C)RT plus TME (5-year LLR, 19.5%; P = .042).

conclusionLLR is still a significant problem after (C)RT plus TME in LLNs with a short axis at least 7 mm on pretreatment MRI. The addition of LLND results in a significantly lower LLR rate.

Indexed as

Chemoradiotherapy, AdjuvantCytoreduction Surgical ProceduresFemaleHumansLymphatic MetastasisLymph NodesMagnetic Resonance ImagingMaleMiddle AgedMultivariate AnalysisNeoadjuvant TherapyNeoplasm Recurrence, LocalNeoplasm StagingRandomized Controlled Trials as TopicRectal Neoplasms

Identifiers

PMID30403572
PMCPMC6366816
OpenAlexW2899619019

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.